Skip to main content

Profile hero

Kristen O. Riemenschneider

Partner

Shortlisted for Life Sciences Lawyer of the Year

Euromoney's Americas Women in Business Law Awards, 2022

Profile details

About Kristen O. Riemenschneider

Kristen represents life sciences companies on their most significant transactions, from strategic license and collaboration transactions to complex supply chain arrangements. She has a deep technical understanding of the life sciences industry, and has negotiated agreements in respect of cutting-edge technologies including gene editing and cell therapies.

Kristen is also nationally recognized for her work counseling life sciences and other companies that engage in US Government-funded research and development. In 2020, Kristen represented several of the most high-profile vaccine manufacturers in their agreements to develop and deliver billions of doses of COVID-19 vaccines to the United States. Overall, she represented more than two dozen companies in negotiations with the US Government for COVID-19 countermeasure funding and support, with agencies including NIH, NCI, BARDA, NIAID and DoD.

Kristen has a degree in engineering and is a registered patent attorney. She is also a Founding Member of Chief DC, a network designed for senior women leaders to strengthen their leadership journey, cross-pollinate ideas across industries, and affect change from the top-down.

Recent work

Life Sciences Transactions

  • AbbVie on a research collaboration and licensing agreement with Caribou Biosciences for Caribou's next-generation Casi2a CRISPR hybrid RNA-DNA genome editing and cell therapy platforms, including a $40 million upfront cash and equity payment, an additional $300 million in payments upon achieving various development milestones and royalties.

  • AstraZeneca on agreements for the funding and global distribution of the University of Oxford's COVID-19 vaccine as well as the establishment of its global manufacturing and supply chain for the vaccine, including agreements with the US Biomedical Advanced Research and Development Authority (BARDA), Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance (Gavi), the Serum Institute of India (SII) and the governments of Germany, France, Italy and the Netherlands.

  • A global pharmaceutical company on the negotiation of an agreement for the supply of a COVID-19 vaccine under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

  • Sanofi on a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases for $150 million upfront and more than $2 billion in potential milestones plus royalties.

  • AstraZeneca on the negotiation of a multi-target research collaboration with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases, including a deal value of $4 billion in development and sales milestones, as well as tiered high single digit to low double-digit royalties.

  • Novartis on the negotiation of license and supply agreements with Spark Therapeutics for ex-US development and commercialization of Luxturna, the first approved gene therapy for an inherited disease, including a deal value of $170 million in achievable milestones as well as royalties.

  • Novartis on the negotiation of an investment with Blackstone for the formation of Anthos Therapeutics, and the related license of MAAA868, an anti-coagulant, to Anthos.

  • Novartis on the negotiation of a supply agreement for the EU production of Kymriah, the first CAR-T cell therapy approved by the United States Food and Drug Administration (FDA).

  • Insmed on the negotiation of a license and collaboration agreement with AstraZeneca regarding an early-stage respiratory drug, including $150 million in achievable milestones and double-digit royalties.

  • Omada Health on a long-term strategic collaboration with Abbott Diabetes Care to integrate Abbott's continuous glucose monitoring (CGM) technology with Omada's professional coaching and digital care platform, aiming to create a new paradigm for people with Type 2 diabetes.

  • AstraZeneca on the negotiation of an agreement for the development and supply of its COVID-19 long-acting antibody under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

  • A biotechnology company on the acquisition of a solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility, which will support the further development of its pipeline of novel cell therapies.

  • Numerous biotechnology and pharmaceutical companies on their negotiations with HHS, BARDA, NIAID and other agencies for the government-supported research and development of COVID-19 diagnostics, therapeutics and vaccines.

Qualifications

Education

  • JD, University of Virginia School of Law
  • BSEE, Electrical Engineering, University of Virginia

Bar Admission

  • District of Columbia
  • Virginia
  • US Patent and Trademark Office